乳腺癌易感基因2抗体elisa实验

乳腺癌易感基因2抗体英文名称  Anti-BRCA2/FANCB 

中文名称  乳腺癌易感基因2抗体 

别    名  BRCA 2; BRCA1/BRCA2 containing complex subunit 2; BRCC 2; BRCC2; Breast and ovarian cancer susceptibility gene early onset; Breast cancer 2 early onset; Breast Cancer 2 tumor suppressor; Breast cancer susceptibility protein BRCA2; Breast cancer type 2 susceptibility protein; FACD; FAD 1; FAD; FAD1; FANCB; FANCD 1; FANCD; FANCD1; Fanconi anemia complementation group D1; Fanconi anemia group D1 protein; OTTHUMP00000018803; OTTHUMP00000042401.  

浓    度  1mg/1ml 

乳腺癌易感基因2抗体规 格  0.1ml/100μg  0.2ml/200μg   

抗体来源  Rabbit  

克隆类型  polyclonal 

交叉反应  Human, Mouse, Rat, Chicken, Dog, Cow, Horse, Rabbit   

产品类型  一抗    

研究领域  肿瘤 细胞生物 免疫学  

蛋白分子量  predicted molecular weight: 384kDa 

性    状  Lyophilized or Liquid 

免 疫 原  KLH conjugated synthetic peptide derived from human BRCA2 

亚    型  IgG 

纯化方法  affinity purified by Protein A 

储 存 液  0.01M PBS, pH 7.4 with 10 mg/ml BSA and 0.1% Sodium azide 

产品应用   ELISA=1:500-1000  IHC-P=1:100-500  IHC-F=1:100-500  IF=1:100-500 

（石蜡切片需做抗原修复） 

 not yet tested in other applications.

 optimal dilutions/concentrations should be determined by the end user.  

保存条件  Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. 

Important Note  This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 

产品介绍 Inherited mutations in BRCA1 and this gene, BRCA2, confer increased lifetime risk of developing breast or ovarian cancer. Both BRCA1 and BRCA2 are involved in maintainance of genome stability, specificallythe homologous recombination pathway for double-strand DNA repair. The BRCA2 protein contains several copies of a 70 aa motif called the BRC motif, and these motifs mediate binding to the RAD51 recombinase which functions in DNA repair. BRCA2 is considered a tumor suppressor gene, as tumors with BRCA2 mutations generally exhibit loss of heterozygosity (LOH) of the wild-type allele.

Function : Involved in double-strand break repair and/or homologous recombination. Binds RAD51 and potentiates recombinational DNA repair by promoting assembly of RAD51 onto single-stranded DNA (ssDNA). Acts by targeting RAD51 to ssDNA over double-stranded DNA, enabling RAD51 to displace replication protein-A (RPA) from ssDNA and stabilizing RAD51-ssDNA filaments by blocking ATP hydrolysis. May participate in S phase checkpoint activation. Binds selectively to ssDNA, and to ssDNA in tailed duplexes and replication fork structures. In concert with NPM1, regulates centrosome duplication.

Subunit : Monomer and dimer. Interacts with RAD51; regulates RAD51 recruitment and function at sites of DNA repair. Interacts with DSS1. Interacts with both nonubiquitinated and monoubiquitinated FANCD2; this complex also includes XRCC3 and phosphorylated FANCG. Interacts with WDR16. Interacts with USP11. Interacts with DMC1. Part of a trimeric complex containing BRCA1, BRCA2 and PALB2. Interacts with PALB2. Interacts with BRCA1 only in the presence of PALB2 which serves as the bridging protein. Interacts with ROCK2 and NPM1.

Subcellular Location : nuclear protein.

Tissue Specificity : Highest levels of expression in breast and thymus, with slightly lower levels in lung, ovary and spleen.

Post-translational modifications : Phosphorylated by ATM upon irradiation-induced DNA damage. Phosphorylation by CHEK1 and CHEK2 regulates interaction with RAD51. Phosphorylation at Ser-3291 by CDK1 and CDK2 is low in S phase when recombination is active, but increases as cells progress towards mitosis; this phosphorylation prevents homologous recombination-dependent repair during S phase and G2 by inhibiting RAD51 binding. 

Ubiquitinated in the absence of DNA damage; this does not lead to proteasomal degradation. In contrast, ubiquitination in response to DNA damage leads to proteasomal degradation.

DISEASE : Defects in BRCA2 are a cause of susceptibility to breast cancer (BC). A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case. Defects in BRCA2 are the cause of pancreatic cancer type 2 (PNCA2) [MIM:613347]. It is a malignant neoplasm of the pancreas. Tumors can arise from both the exocrine and endocrine 乳腺癌易感基因2抗体portions of the pancreas, but 95% of them develop from the exocrine portion, including the ductal epithelium, acinar cells, connective tissue, and lymphatic tissue. 

Similarity : Contains 8 BRCA2 repeats.

Database links : UniProtKB/Swiss-Prot: P51587.2 

BRCA2蛋白与DNA修复和重组有关， 乳腺癌易感基因其突变和家族性乳腺癌、卵巢癌的发病有关。

BRCA2是新近发现的一个抑癌基因，它在流行病学上与早期发现的BRCA1有许多相似之处。有学者发现：BRCA2在其它BRCA2突变的家族中也发现多发有结肠癌、肺癌、输尿管癌、脑瘤、胰腺癌和白血病等。BRCA2突变家族中这种肿瘤的多样性在其它研究中也有报道。